Tenon Medical Reports 90% Revenue Increase to $1.38 Million in Q1 2026

Tenon Medical, Inc. reported a significant increase in revenue for the first quarter of 2026, achieving $1.38 million compared to $726,000 in the same period of 2025, marking a 90% increase. The company's gross profit also rose to $945,000, up from $323,000, resulting in a gross margin of 69%, compared to 44% in the prior year. This growth is attributed to an increase in surgical procedures and the addition of revenue from the recently acquired SImmetry+ System, which treats sacroiliac joint disorders.

Despite the revenue growth, Tenon Medical continues to face challenges with profitability, reporting a net loss of $3.48 million for the quarter, slightly improved from a loss of $3.62 million in the previous year. Operating expenses increased to $4.23 million, up from $4 million, driven primarily by higher sales and marketing costs, which rose by 13% to $1.86 million. Research and development expenses decreased slightly by 4% to $662,000, reflecting a reduction in stock-based compensation and payroll expenses.

The company’s balance sheet as of March 31, 2026, showed total assets of $12.84 million, an increase from $10.76 million at the end of 2025. Cash and cash equivalents rose to $4.61 million from $3.76 million, while total liabilities increased significantly to $10.94 million, up from $5.72 million, largely due to the issuance of convertible notes totaling $3.48 million. The accumulated deficit also grew to approximately $84.78 million, indicating ongoing financial challenges.

In terms of strategic developments, Tenon Medical completed the acquisition of SiVantage, Inc. and SIMPL Medical, LLC in August 2025, which included the SImmetry+ System. This acquisition is expected to enhance the company’s product offerings and market presence. Additionally, the company has expanded its intellectual property portfolio, receiving Notices of Allowance for multiple patent applications, which are anticipated to strengthen its competitive position in the medical device market.

Looking ahead, Tenon Medical anticipates continued revenue growth driven by increased adoption of its products and expansion into new markets. However, the company has expressed concerns regarding its ability to sustain operations without additional capital, as existing cash reserves may not cover operational expenses for the next 12 months. Management plans to pursue various financing options, including public or private equity offerings and debt financing, to support ongoing operations and product development. The company remains under scrutiny from Nasdaq for not maintaining the minimum bid price for its stock, which could impact its listing status if not resolved by August 2026.